WATCHMAN FLX Device Shows Superior Bleeding Protection, Similar Stroke Reduction to Blood Thinners in CHAMPION-AF Trial
summarizeSummary
Boston Scientific announced highly positive results from its CHAMPION-AF global clinical trial for the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device. The trial successfully met all primary and secondary safety and efficacy endpoints, demonstrating statistically superior protection from bleeding and similar efficacy in reducing stroke risk compared to non-vitamin K antagonist oral anticoagulants (NOACs) as a first-line therapy for non-valvular atrial fibrillation (NVAF) patients. These strong results, presented at the American College of Cardiology's Annual Scientific Session & Expo and published in The New England Journal of Medicine, validate the WATCHMAN FLX device as a safe and effective alternative to long-term anticoagulant therapy. This could significantly expand the addressable market for WATCHMAN FLX, drive increased adoption, and strengthen Boston Scientific's competitive position in the stroke prevention market, potentially boosting future revenue growth. Investors should monitor regulatory submissions based on these results and the subsequent market adoption and sales trajectory of the WATCHMAN FLX device.
At the time of this announcement, BSX was trading at $69.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $102.6B. The 52-week trading range was $67.56 to $109.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.